Is pharma in for a swarm of subpoenas? Are we running out of ideas in oncology? And can a drug possibly be worth $4 million a dose?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Lev Facher joins us to recap the midterms, going over what the new Congress has in store for drug prices, victories for anti-pharma crusaders, and the end of former Celgene CEO Bob Hugin’s campaign for Senate. Then, on the eve of a major cancer conference, we’ll dig into how the seemingly bright future for combining immuno-oncology drugs has led to surprising disappointment. Finally, a new gene therapy from Novartis has showed dramatic effects on a rare and deadly disease. The company says it would be cost-effective with a $4 million price tag, and not everyone agrees.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • 4 Million $/mo ?

    Talk about high pricing!

    Would there be consideration for their parents if they were affected?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy